JP2020506898A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506898A5
JP2020506898A5 JP2019538383A JP2019538383A JP2020506898A5 JP 2020506898 A5 JP2020506898 A5 JP 2020506898A5 JP 2019538383 A JP2019538383 A JP 2019538383A JP 2019538383 A JP2019538383 A JP 2019538383A JP 2020506898 A5 JP2020506898 A5 JP 2020506898A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
polypeptide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019538383A
Other languages
English (en)
Japanese (ja)
Other versions
JP7300385B2 (ja
JP2020506898A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/051082 external-priority patent/WO2018134234A1/en
Publication of JP2020506898A publication Critical patent/JP2020506898A/ja
Publication of JP2020506898A5 publication Critical patent/JP2020506898A5/ja
Priority to JP2022168448A priority Critical patent/JP7585272B2/ja
Application granted granted Critical
Publication of JP7300385B2 publication Critical patent/JP7300385B2/ja
Priority to JP2024194438A priority patent/JP2025024012A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019538383A 2017-01-17 2018-01-17 改善された血清アルブミン結合剤 Active JP7300385B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022168448A JP7585272B2 (ja) 2017-01-17 2022-10-20 改善された血清アルブミン結合剤
JP2024194438A JP2025024012A (ja) 2017-01-17 2024-11-06 改善された血清アルブミン結合剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762446992P 2017-01-17 2017-01-17
US62/446,992 2017-01-17
PCT/EP2018/051082 WO2018134234A1 (en) 2017-01-17 2018-01-17 Improved serum albumin binders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022168448A Division JP7585272B2 (ja) 2017-01-17 2022-10-20 改善された血清アルブミン結合剤

Publications (3)

Publication Number Publication Date
JP2020506898A JP2020506898A (ja) 2020-03-05
JP2020506898A5 true JP2020506898A5 (enExample) 2021-01-07
JP7300385B2 JP7300385B2 (ja) 2023-06-29

Family

ID=61163666

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019538383A Active JP7300385B2 (ja) 2017-01-17 2018-01-17 改善された血清アルブミン結合剤
JP2022168448A Active JP7585272B2 (ja) 2017-01-17 2022-10-20 改善された血清アルブミン結合剤
JP2024194438A Pending JP2025024012A (ja) 2017-01-17 2024-11-06 改善された血清アルブミン結合剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022168448A Active JP7585272B2 (ja) 2017-01-17 2022-10-20 改善された血清アルブミン結合剤
JP2024194438A Pending JP2025024012A (ja) 2017-01-17 2024-11-06 改善された血清アルブミン結合剤

Country Status (22)

Country Link
US (2) US11897944B2 (enExample)
EP (3) EP4471058A3 (enExample)
JP (3) JP7300385B2 (enExample)
KR (2) KR20230165374A (enExample)
CN (2) CN117327175A (enExample)
AU (2) AU2018209150B2 (enExample)
BR (1) BR112019014600A2 (enExample)
CA (1) CA3050574A1 (enExample)
DK (1) DK3571224T3 (enExample)
ES (1) ES2994387T3 (enExample)
FI (1) FI3571224T3 (enExample)
HR (1) HRP20241501T1 (enExample)
HU (1) HUE068820T2 (enExample)
IL (3) IL316293A (enExample)
LT (1) LT3571224T (enExample)
MX (4) MX2019008536A (enExample)
PL (1) PL3571224T3 (enExample)
PT (1) PT3571224T (enExample)
RS (1) RS66173B1 (enExample)
SG (2) SG10202108973SA (enExample)
SI (1) SI3571224T1 (enExample)
WO (1) WO2018134234A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
SG11201609162SA (en) 2014-05-16 2016-12-29 Ablynx Nv Improved immunoglobulin variable domains
EP3551656A1 (en) * 2016-12-07 2019-10-16 Ablynx NV Improved serum albumin binding immunoglobulin single variable domains
DK3571224T3 (da) * 2017-01-17 2024-11-11 Ablynx Nv Forbedrede serumalbuminbindere
CN117285623A (zh) * 2017-01-17 2023-12-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
JP7657797B2 (ja) 2019-12-06 2025-04-07 アブリンクス エン.ヴェー. TNFαおよびIL-23を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
MX2022006881A (es) 2019-12-06 2022-07-11 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l.
IL293548A (en) 2019-12-09 2022-08-01 Ablynx Nv Polypeptides comprising immunoglobulin with single variable domains targeting 13 il and tsl
CA3175873A1 (en) 2020-03-30 2021-10-07 Ablynx Nv Method for the production and purification of multivalent immunoglobulin single variable domains
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2022063984A1 (en) 2020-09-25 2022-03-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
EP4237438A4 (en) * 2020-10-27 2024-11-27 Beijing QL Biopharmaceutical Co., Ltd. GDF15 FUSION PROTEINS AND THEIR USE
CA3203141A1 (en) 2020-12-18 2022-06-23 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
JP7842101B2 (ja) 2020-12-18 2026-04-07 アブリンクス エン.ヴェー. IL-6およびTNF-αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
TW202241947A (zh) 2020-12-18 2022-11-01 比利時商艾伯霖克斯公司 包含靶向磷脂醯肌醇蛋白聚糖—3和t細胞受體的免疫球蛋白單可變結構域的多肽
AU2022409733A1 (en) 2021-12-17 2024-08-01 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
CN119604536A (zh) * 2022-05-23 2025-03-11 塞雷乌斯股份有限公司 Her2结合剂及其用途
CA3259417A1 (en) 2022-06-14 2023-12-21 Ablynx Nv UNIQUE VARIABLE DOMAINS OF IMMUNOGLOBULIN TARGETING THE T LYMPHOCYTE RECEPTOR
KR20250042176A (ko) 2022-07-27 2025-03-26 아블린쓰 신생아 fc 수용체의 특정 에피토프에 결합하는 폴리펩타이드
CN120529914A (zh) 2023-01-09 2025-08-22 奥德赛治疗股份有限公司 抗tnfr2抗原结合蛋白及其用途
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
IL323035A (en) 2023-03-14 2025-10-01 Odyssey Therapeutics Inc Anti-CD25 antigen-binding proteins and their uses
CN121511255A (zh) 2023-05-17 2026-02-10 奥德赛治疗股份有限公司 经修饰的单结构域抗体
EP4731770A1 (en) 2023-06-22 2026-04-29 Ablynx NV Chimeric proteins for modulating cytokine receptor activity
KR20260032566A (ko) 2023-06-29 2026-03-09 오디세이 테라퓨틱스, 인코포레이티드 항-trailr2 항원-결합 단백질 및 그의 용도
CN121443644A (zh) 2023-07-05 2026-01-30 阿布林克斯有限公司 用于治疗IgG相关疾病和障碍的改善的FcRn拮抗剂
AR133725A1 (es) 2023-09-04 2025-10-29 Sanofi Sa Polipéptidos para uso en el tratamiento de tumores que expresan glipicano-3
CN121986112A (zh) 2023-09-22 2026-05-05 阿布林克斯有限公司 二价和多价白蛋白结合剂
WO2025080751A2 (en) 2023-10-13 2025-04-17 Odyssey Therapeutics, Inc. Anti-cdh17 antigen-binding proteins and uses thereof
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
AR134512A1 (es) 2023-12-01 2026-01-21 Ablynx Nv Polipéptidos activados con precisión
TW202543670A (zh) 2023-12-22 2025-11-16 比利時商艾伯霖克斯公司 用於核內投予之基於蛋白質的接合載劑
AR134804A1 (es) 2023-12-22 2026-04-01 Ablynx Nv Portadores a base de proteínas para la conjugación de aminas específicas de sitio
TW202602941A (zh) 2024-04-10 2026-01-16 美商奧迪希治療公司 抗tnfr2抗原結合蛋白及其用途
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2026006809A1 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof
WO2026006708A2 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof
WO2026052756A1 (en) 2024-09-05 2026-03-12 Ablynx Nv Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof
WO2026078159A1 (en) 2024-10-10 2026-04-16 Ablynx Nv Immune cell engagers and methods comprising the same

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1999023221A2 (en) 1997-10-27 1999-05-14 Unilever Plc Multivalent antigen-binding proteins
US6742038B2 (en) 2000-04-07 2004-05-25 Danger, Inc. System and method of linking user identification to a subscriber identification module
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
CA2588892A1 (en) 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
MX2007014564A (es) 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
CN101454344A (zh) 2005-12-01 2009-06-10 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的非竞争性域抗体形式
KR20080077237A (ko) 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 경쟁적 도메인 항체포맷
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
WO2007085814A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CN101646689A (zh) 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
KR101264473B1 (ko) 2007-05-24 2013-05-29 아블린쓰 엔.브이. Rank-l에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
WO2009068631A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
EP2454285A2 (en) 2009-07-16 2012-05-23 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
SG10201406063XA (en) 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
SG188204A1 (en) 2010-08-20 2013-04-30 Glaxo Group Ltd Improved anti-serum albumin binding variants
US11644471B2 (en) * 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) * 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
EP3466972B1 (en) 2011-06-23 2026-03-04 Ablynx NV Serum albumin binding proteins
HUE031828T2 (en) * 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
US20150344568A1 (en) * 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012174741A1 (en) 2011-06-24 2012-12-27 Google Inc. Determining cross-language query suggestion based on query translations
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
WO2014037419A1 (en) * 2012-09-04 2014-03-13 Vib Vzw Immunoglobulin single variable domains directed against cd74 and uses derived thereof
US20140186365A1 (en) * 2013-01-03 2014-07-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
SG11201609162SA (en) 2014-05-16 2016-12-29 Ablynx Nv Improved immunoglobulin variable domains
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス,インコーポレイティド 非免疫原性単一ドメイン抗体
PT3294768T (pt) 2015-05-13 2019-11-05 Ablynx Nv Polipétidos de recrutamento de células t com base na reatividade do tcr alfa/beta
AU2016342048B2 (en) 2015-10-22 2022-09-08 Modernatx, Inc. Broad spectrum influenza virus vaccine
CN108473561B (zh) 2015-11-27 2022-12-16 埃博灵克斯股份有限公司 抑制cd40l的多肽
WO2017189964A2 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3551656A1 (en) * 2016-12-07 2019-10-16 Ablynx NV Improved serum albumin binding immunoglobulin single variable domains
CN117285623A (zh) * 2017-01-17 2023-12-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
DK3571224T3 (da) 2017-01-17 2024-11-11 Ablynx Nv Forbedrede serumalbuminbindere

Similar Documents

Publication Publication Date Title
JP2020515518A5 (enExample)
JP7453206B2 (ja) 改良された血清アルブミン結合剤
JP7840836B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP7304375B2 (ja) 血清アルブミンに結合するタンパク質
RU2022101604A (ru) Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
IL316293A (en) Improved serum albumin binders
CN110382529B (zh) 工程化的异源二聚体蛋白质
JP2020500510A5 (enExample)
JP2021512159A5 (enExample)
JPWO2020059847A5 (enExample)
JP2022532370A5 (enExample)
JP2024535851A5 (enExample)
RU2023110757A (ru) Усовершенствованные агенты, связывающие сывороточный альбумин
RU2023102139A (ru) Усовершенствованные связывающиеся с сывороточным альбумином вещества
RU2019125831A (ru) Усовершенствованные связывающиеся с сывороточным альбумином вещества
CA3005061C (en) Improved serum albumin-binding immunoglobulin variable domains
RU2019118441A (ru) Рекрутирующие т-клетки полипептиды, способные связывать cd123 и tcr альфа/бета